Navigation Links
Ambry Genetics Reports Results from Clinical Diagnostic Exome™ Testing of Three Patients
Date:1/19/2012

ALISO VIEJO, Calif., Jan. 19, 2012 /PRNewswire/ -- Ambry Genetics, a global leader in genetic services with a focus on clinical diagnostics and genomics, announces the successful completion of the first three diagnostic cases using its proprietary Clinical Diagnostic Exome™.  Three individuals suffering from symptoms for which the cause could not be identified were successfully diagnosed.

(Logo:  http://photos.prnewswire.com/prnh/20110307/LA59848LOGO)

"This marks a pivotal moment for clinical diagnostics," said Charles Dunlop, chief executive officer of Ambry Genetics. "A full diagnostic exome test with a high percentage of diagnosis is potentially a game changer for how clinicians approach diagnostics.  Some of these families have been trying to figure out what was ailing their children for years, and we solved the riddle in weeks. Our exome test is being covered by major national health insurance carriers, making it available to much of the population.  We will be able to help many people suffering from undiagnosed conditions, and nothing makes me more thrilled as a scientist and chief executive."

Ambry Genetics was the first CLIA-certified laboratory to offer whole exome sequencing for clinical diagnostics, and the company believes that its Clinical Diagnostic Exome test is the first to deliver clinical results.  

Wenqi Zeng, PhD., director of clinical genomics at Ambry Genetics added additional perspective, "We're now finding the cause of the disease much faster because we are able to look into the patients blueprint. This is essentially a human genome project for an individual patient."

"The Clinical Diagnostic Exome offers hope to those suffering from previously-undiagnosed conditions," said Elizabeth Chao, M.D., assistant medical director of Ambry Genetics. "We anticipate being able to share more details about these specific cases in the coming weeks."

About Ambry Genetics®

Ambry Genetics is a CAP-accredited and CLIA-certified commercial clinical laboratory with headquarters in Aliso Viejo, California. Since the company's inception in 1999, it has become a leader in providing genetic services focused on clinical diagnostics and genomic services, particularly sequencing and array services. Ambry has established a solid reputation for unparalleled service and has been at the forefront of applying new technologies to the clinical molecular diagnostics market and to the advancement of disease research. To learn more about testing and services available through Ambry Genetics, visit www.ambrygen.com.


'/>"/>
SOURCE Ambry Genetics
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. Ambry Genetics Announces Certified Service Provider Status for Agilent Microarrays
2. American College of Medical Genetics receives $13.5M NIH contract
3. The American Society of Human Genetics hosts 58th Annual Meeting in Philadelphia
4. Modern genetics vs. ancient frog-killing fungus
5. New research helps explain genetics of Parkinsons disease
6. New genetic markers for ulcerative colitis identified, researchers report in Nature Genetics
7. Far-reaching genetics topics to be addressed: 2009 Annual Clinical Genetics Meeting, March 25-29
8. Study examining role of genetics and environment in type 1 diabetes
9. The genetics of fear: Study suggests specific genetic variations contribute to anxiety disorders
10. Roberta A. Pagon receives lifetime award in genetics from March of Dimes
11. Margarita Saenz, M.D. is recipient of Genzyme/ACMGF Fellowship in Biochemical Genetics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
Breaking Biology News(10 mins):
(Date:6/22/2016)... NEW YORK , June 22, 2016 /PRNewswire/ ... the growing next generation sequencing (NGS) market include ... adoption of smaller sequencers.  More accessible and affordable ... led to growing demand for consumables including sample ... The Market for Sample Preparation for Next ...
(Date:6/22/2016)... , June 22, 2016   ViaCyte, Inc. , ... stem cell-derived islet replacement therapy for the treatment of ... ISSCR 2016 Annual Meeting.  ISSCR 2016, the Global Stem ... at Moscone West in San Francisco.  ... presentations are as follows:Event: , Focus Session: Tools for ...
(Date:6/22/2016)... 2016  Mesa Biotech Inc., a privately-held, molecular ... designed specifically for point-of-care (POC) infectious disease diagnosis, ... board (SAB). Approved by the executive leadership team ... to advise on the development and commercialization of ... Dr. Steve Young , this world-class team ...
(Date:6/21/2016)... NANJING , China , June ... that a Phase 2 clinical trial for its novel ... statistically significant (p=0.023) and clinically meaningful pain relief against ... the United States , the trial enrolled 146 ... statistically significant (1) analgesia against placebo at week-1 (p=0.024), ...
Breaking Biology Technology: